Sharyn Alfonsi reports on the unusual path fluvoxamine, a drug commonly used to treat obsessive-compulsive disorder, has had to becoming an early treatment candidate for COVID-19
Antidepressant drug repurposed for patients with coronavirus infection
Research into psychological disorders, Alzheimer’s disease earned the two one of the most prestigious honors in health, medical field
Fear of contracting or spreading COVID-19 might be increasing the severity of these symptoms, notes Dr. Cynthia Rogers.
The Food and Drug Administration has approved a variant of the anesthetic and party drug ketamine for suicidal patients with major depression.
Joan Luby, MD, director of the School of Medicine’s Early Emotional Development Program and the Samuel and Mae S. Ludwig Professor of Child Psychiatry, will receive the Carl and Gerty Cori Faculty Achievement Award. Douglas F. Covey, the Andrew C. and Barbara B. Taylor Distinguished Professor of Psychiatry at the School of Medicine, will receive […]
Researchers in St. Louis have launched a study into whether a long-used antidepressant can reduce the likelihood that COVID-19 will turn deadly.
Researchers at Washington University School of Medicine are recruiting COVID-19 patients for a clinical trial that will examine whether an existing anti-depressant can be an effective treatment for COVID-19.
Washington University in St. Louis will begin construction in March on what will be one of the largest neuroscience research buildings in the country.
Neuroactive steroid drugs result from Taylor Family Institute, pharma collaboration
Professorship supports research in new treatment strategies for psychiatric illness
Glowinski, artist Outlaw address mental health through artwork.